Need Help?

Sequencing of an organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.

Kidney tumors are among the most common solid tumors in children, comprising several distinct subtypes differing in many aspects, including cell-of-origin, genetics, and pathology. Pre-clinical cell models capturing the disease heterogeneity are currently lacking. Here, we describe the first pediatric cancer organoid biobank. It contains tumor and matching normal organoids from over 50 children with different subtypes of kidney cancer, including Wilms tumors, malignant rhabdoid tumors, renal cell carcinomas, and congenital mesoblastic nephromas. The malignant rhabdoid tumor organoids represent the first organoid model for tumors of non-epithelial origin. The tumor organoids retain key properties of native tumors, useful for revealing patient specific drug vulnerabilities. We further demonstrate that organoid cultures derived from Wilms tumors consist of multiple different cell types, including epithelial, stromal and blastemal-like. Our organoid biobank captures the cellular heterogeneity of pediatric kidney tumors, providing a representative collection of well-characterized models for basic cancer research, drug-screening, and personalized medicine.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001005318 Illumina HiSeq 4000 51
EGAD00001005319 BGISEQ-500 HiSeq X Ten Illumina NovaSeq 6000 59
EGAD00001006574 Illumina NovaSeq 6000 30
EGAD00001007498 NextSeq 500 1
EGAD00001007947 Illumina HiSeq 4000 3
EGAD00001007948 Illumina HiSeq 4000 Illumina NovaSeq 6000 6
Publications Citations
An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
Nat Commun 11: 2020 1310
128
Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours.
Nat Commun 12: 2021 1407
37
Single cell derived mRNA signals across human kidney tumors.
Nat Commun 12: 2021 3896
21
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.
Nat Commun 14: 2023 7762
5